We chose to follow up on CD90, as it has been reported by others to be expressed on mesenchymal stem cells [18], on cells resembling mesenchymal stem cells that were cultured from SOC samples [19], and also to be a CAF marker in prostate cancer [20], [21]. This evidence concerns the gene THY1 and prostate carcinoma.